Impaired nerve conduction velocity in MPTP-treated mouse model of Parkinson's disease

References

• Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19–34.
   Google Scholar
• Valls-Solé J. Neurophysiological characterization of parkinsonian syndromes. Neurophysiol Clin 2000;30:352–67.
   PubMedGoogle Scholar
• DeVos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008;31:151–73.
   PubMedGoogle Scholar
• Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010;68:28–36.
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Marchese R, Trompetto C. Sensory and motor evoked potentials in multiple system atrophy: a comparative study with Parkinson's disease. Mov Disord 1997;12:315–21.
   PubMed Web of Science ®Google Scholar
• Mochio S, Oka H, Katayama K, Sato H. Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity. Nihon Rinsho 1997;55:173–8.
   PubMedGoogle Scholar
• Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949–56.
   PubMed Web of Science ®Google Scholar
• Arai N, Misugi K, Goshima Y, Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 1990; 515:57–63.
   PubMed Web of Science ®Google Scholar
• Tariq M, Khan HA, Al Moutaery K, Al Deeb S. Effect of chronic administration of magnesium sulfate on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Pharmacol Toxicol 1998;82:218–22.
   PubMedGoogle Scholar
• Khasnavis S, Roy A, Ghosh S, et al. Protection of dopaminergic neurons in a mouse model of Parkinson's disease by a physically-modified saline containing charge-stabilized nanobubbles. J Neuroimmune Pharmacol 2014;9:218–32.
   PubMed Web of Science ®Google Scholar
• Chiueh CC, Wu RM, Mohanakumar KP, et al. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann N Y Acad Sci 1994;738:25–36.
   PubMed Web of Science ®Google Scholar
• Park SW, Kim SH, Park KH, et al., 2004. Preventive effects of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci Lett 2004;363:243–6.
   PubMed Web of Science ®Google Scholar
• Khan HA. Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice. Neurochem Int 2010;57:489–91.
   PubMed Web of Science ®Google Scholar
• Tariq M, Khan HA, Moutaery KA, Al Deeb S. Dipyridamole potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinsonism in mice. Parkinsonism Relat Disord 1998;4:43–50.
   PubMedGoogle Scholar
• Tariq M, Khan HA, Al Moutaery K, Al Deeb S. Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res Bull 2001;54:77–82.
   PubMedGoogle Scholar
• Khan HA. Detection and semi-quantitative determination of low abundance GFAP mRNA in mouse brain by capillary electrophoresis coupled with laser-induced fluorescence. Brain Res Brain Res Protoc 2004;14:13–7.
   PubMedGoogle Scholar
• Khan HA. Time-course evaluation of whole blood phagocytosis in mice treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Inflammopharmacology 2004;12:81–8.
   PubMedGoogle Scholar
• Kim HG, Ju MS, Ha SK, et al. Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. Biol Pharm Bull 2012;35:1287–94.
   PubMed Web of Science ®Google Scholar
• Episcopo FL, Tirolo C, Testa N, et al. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. Curr Aging Sci 2013;6:45–55.
   PubMedGoogle Scholar
• Khan MM, Kempuraj D, Thangavel R, Zaheer A. Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol. Neurochem Int 2013;62:379–88.
   PubMedGoogle Scholar
• Ulivelli M, Rossi S, Pasqualetti P, et al. Time course of frontal somatosensory evoked potentials. Relation to L-dopa plasma levels and motor performance in PD. Neurology 1999;53:1451–7.
   PubMedGoogle Scholar
• Mak M, Hallett M. Effect of cued training on motor evoked potential and cortical silent period in people with Parkinson's disease. Clin Neurophysiol 2013;124:545–50.
   PubMedGoogle Scholar
• Wu AD, Petzinger GM, Lin CH, et al. Asymmetric corticomotor excitability correlations in early Parkinson's disease. Mov Disord 2007;22:1587–93.
   PubMedGoogle Scholar
• Caviness JN, Smith BE, Clarke Stevens J, et al. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2002;8:161–4.
   PubMedGoogle Scholar
• Dick JP, Cowan JM, Day BL, et al. The corticomotoneurone connection is normal in Parkinson's disease. Nature 1984;310:407–9.
   PubMedGoogle Scholar
• Perretti A, De Rosa A, Marcantonio L, et al. Neurophysiological evaluation of motor corticospinal pathways by TMS in idiopathic early-onset Parkinson's disease. Clin Neurophysiol 2011;122:546–9.
   PubMedGoogle Scholar
• Deniau JM, Hammond C, Riszk A, Feger J. Electrophysiological properties of identified output neurons of the rat substantia nigra (pars compacta and pars reticulata): evidences for the existence of branched neurons. Exp Brain Res 1978;32:409–22.
   PubMed Web of Science ®Google Scholar
• Guyenet PG, Aghajanian GK. Antidromic identification of dopaminergic and other output neurons of the rat substantia nigra. Brain Res 1978;150:69–84.
   PubMedGoogle Scholar
• Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 1983;10:301–15.
   PubMedGoogle Scholar
• Chovancova Z, Kanovsky P, Dufek J, et al. Peripheral nerve involvement and severity of motor disorder in Parkinson's disease: a correlational study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:59–62.
   PubMedGoogle Scholar
• Ohsawa Y, Kurokawa K, Sonoo M, et al. Reduced amplitude of the sural nerve sensory action potential in PARK2 patients. Neurology 2005;65:459–62.
   PubMedGoogle Scholar
• Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008;131:1903–11.
   PubMed Web of Science ®Google Scholar
• Wszolek ZK, Lagerlund TD, Steg RE, McManis PG. Clinical neurophysiologic findings in patients with rapidly progressive familial parkinsonism and dementia with pallido-ponto-nigral degeneration. Electroencephalogr Clin Neurophysiol 1998;107:213–22.
   PubMedGoogle Scholar